Brought to you by

Ferring licenses Ligand's OmniAb antibodies platform
23 Jan 2018
Executive Summary
Ligand Pharmaceuticals Inc. licensed worldwide rights to its OmniAb antibody platform to Ferring Pharmaceuticals.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com